Published in Ann Biomed Eng on October 30, 2011
Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells. Clin Proteomics (2015) 0.80
Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells. Oncotarget (2016) 0.78
Sialidases as regulators of bioengineered cellular surfaces. Glycobiology (2015) 0.77
Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example. Biomaterials (2016) 0.75
Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications. Glycoconj J (2015) 0.75
Cell surface engineering by a modified Staudinger reaction. Science (2000) 8.09
Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell (2000) 3.95
Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science (1997) 3.34
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature (2001) 3.09
A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci U S A (2003) 2.97
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells. Proc Natl Acad Sci U S A (2007) 2.78
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A (2008) 2.62
The glycosynapse. Proc Natl Acad Sci U S A (2002) 2.46
Metabolism, cell surface organization, and disease. Cell (2009) 2.41
N-Glycans in cancer progression. Glycobiology (2008) 2.35
Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol (2002) 2.27
Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol (2005) 2.22
Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology. Nat Chem Biol (2006) 1.98
Rolling cell adhesion. Annu Rev Cell Dev Biol (2010) 1.97
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
Probing mucin-type O-linked glycosylation in living animals. Proc Natl Acad Sci U S A (2006) 1.85
Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets (2007) 1.82
The emerging significance of O-GlcNAc in cellular regulation. Chem Rev (2002) 1.65
The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem (2002) 1.61
Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-D-hexosamines as precursors. J Biol Chem (1992) 1.59
Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol (2011) 1.59
Modifying the mechanical property and shear threshold of L-selectin adhesion independently of equilibrium properties. Nature (1998) 1.50
Metabolic glycoengineering: sialic acid and beyond. Glycobiology (2009) 1.45
Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Mol Biosyst (2007) 1.32
Metabolic delivery of ketone groups to sialic acid residues. Application To cell surface glycoform engineering. J Biol Chem (1998) 1.32
PSGL-1 function in immunity and steady state homeostasis. Immunol Rev (2009) 1.31
Substrate specificity of the sialic acid biosynthetic pathway. Biochemistry (2001) 1.31
Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J (2005) 1.28
Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents (2001) 1.27
Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj J (2004) 1.26
Photoactivatable crosslinking sugars for capturing glycoprotein interactions. J Am Chem Soc (2008) 1.24
Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine. Biochemistry (2006) 1.24
Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J Biol Chem (2001) 1.22
Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem (2011) 1.17
Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuraminic acid precursor. J Biol Chem (1998) 1.16
Kinetic parameters for small-molecule drug delivery by covalent cell surface targeting. Biochim Biophys Acta (2001) 1.14
Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol (2007) 1.13
Carbohydrate-carbohydrate interactions in cell recognition. Curr Opin Struct Biol (2004) 1.13
GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism. J Biol Chem (2002) 1.12
Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 and reduces cell binding to selectins. Blood (2009) 1.10
Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells. J Biol Chem (2004) 1.09
Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol (2006) 1.09
Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. J Med Chem (2008) 1.07
Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression. ACS Chem Biol (2008) 1.06
Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J Med Chem (2009) 1.03
Engineering the sialic acid in organs of mice using N-propanoylmannosamine. Biochim Biophys Acta (2006) 1.02
Molecular basis of the dynamic strength of the sialyl Lewis X--selectin interaction. Chemphyschem (2004) 1.01
Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology (2008) 1.00
Sialic acid metabolism is involved in the regulation of gene expression during neuronal differentiation of PC12 cells. Glycoconj J (2008) 0.98
Hexosamine analogs: from metabolic glycoengineering to drug discovery. Curr Opin Chem Biol (2009) 0.97
Biological water and its role in the effects of alcohol. Alcohol (1998) 0.97
Engineering sialic acid synthetic ability into insect cells: identifying metabolic bottlenecks and devising strategies to overcome them. Biochemistry (2003) 0.96
Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J Biol Chem (2009) 0.96
Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chem Biol (2006) 0.92
Fluorination of mammalian cell surfaces via the sialic acid biosynthetic pathway. Bioorg Med Chem Lett (2008) 0.92
Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS One (2009) 0.92
Understanding carbohydrate-carbohydrate interactions by means of glyconanotechnology. Glycoconj J (2004) 0.90
Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents. Curr Opin Chem Biol (1998) 0.89
Modulation of cellular adhesion by glycoengineering. J Med Chem (2010) 0.86
Enzymatic introduction of a fluorescent sialic acid into oligosaccharide chains of glycoproteins. Eur J Biochem (1988) 0.85
Transfer of synthetic sialic acid analogues to N- and O-linked glycoprotein glycans using four different mammalian sialyltransferases. Biochemistry (1989) 0.84
Modification of sialic acid metabolism of murine erythroleukemia cells by analogs of N-acetylmannosamine. Biochim Biophys Acta (1983) 0.83
Glycosphingolipids of skeletal muscle: II. Modulation of Ca2(+)-flux in triad membranes by gangliosides. Carbohydr Res (1998) 0.82
Membrane adhesion via homophilic saccharide-saccharide interactions investigated by neutron scattering. Biophys J (2011) 0.82
Cooperation between lateral ligand mobility and accessibility for receptor recognition in selectin-induced cell rolling. Biochemistry (2002) 0.81
Antagonistic effect of ganglioside GM1 and GM3 on the activity and conformation of sarcoplasmic reticulum Ca(2+)-ATPase. FEBS Lett (1999) 0.81
Rolling on N-linked glycans: a new way to present L-selectin binding sites. Nat Immunol (2007) 0.78
N-acetyl-D-mannosamine analogues as potential inhibitors of sialic acid biosynthesis. J Pharm Sci (1983) 0.78
Computational modeling of carbohydrate-recognition process in E-selectin complex: structural mapping of sialyl Lewis X onto ab initio QM/MM free energy surface. J Phys Chem B (2010) 0.78
Bending rigidities of cell surface molecules P-selectin and PSGL-1. J Biomech (2009) 0.78
Lessons learned from clustering of fluorinated glycolipids on selectin ligand function in cell rolling. Biochemistry (2006) 0.77
Gangliosides, or sialic acid, antagonize ethanol intoxication. Life Sci (1988) 0.76
Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology. Nat Chem Biol (2006) 1.98
Metabolic glycoengineering: sialic acid and beyond. Glycobiology (2009) 1.45
Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Mol Biosyst (2007) 1.32
Characterization of the cellular uptake and metabolic conversion of acetylated N-acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnol Bioeng (2004) 1.20
Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol Cell Proteomics (2012) 1.13
GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism. J Biol Chem (2002) 1.12
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
The systems biology of glycosylation. Chembiochem (2004) 1.09
Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells. J Biol Chem (2004) 1.09
Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. J Med Chem (2008) 1.07
Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression. ACS Chem Biol (2008) 1.06
Carbohydrate engineered cells for regenerative medicine. Adv Drug Deliv Rev (2010) 1.04
Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J Med Chem (2009) 1.03
The effect of nanofiber-guided cell alignment on the preferential differentiation of neural stem cells. Biomaterials (2010) 1.03
Mass spectrometric analysis of sialylated glycans with use of solid-phase labeling of sialic acids. Anal Chem (2013) 1.01
A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. Glycobiology (2009) 1.01
Gangliogenesis in the enteric nervous system: roles of the polysialylation of the neural cell adhesion molecule and its regulation by bone morphogenetic protein-4. Dev Dyn (2007) 1.00
Hexosamine analogs: from metabolic glycoengineering to drug discovery. Curr Opin Chem Biol (2009) 0.97
Engineering sialic acid synthetic ability into insect cells: identifying metabolic bottlenecks and devising strategies to overcome them. Biochemistry (2003) 0.96
Large-scale approaches for glycobiology. Genome Biol (2005) 0.96
Nephrinuria associates with multiple renal traits in type 2 diabetes. Nephrol Dial Transplant (2010) 0.96
Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol Bioeng (2011) 0.92
Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chem Biol (2006) 0.92
Synthesis of non-natural ManNAc analogs for the expression of thiols on cell-surface sialic acids. Nat Protoc (2006) 0.91
Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One (2010) 0.90
Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnol Prog (2004) 0.90
Glycosylation changes as markers for the diagnosis and treatment of human disease. Biotechnol Genet Eng Rev (2003) 0.87
Designing a binding interface for control of cancer cell adhesion via 3D topography and metabolic oligosaccharide engineering. Biomaterials (2011) 0.86
Metabolic expression of thiol-derivatized sialic acids on the cell surface and their quantitative estimation by flow cytometry. Nat Protoc (2006) 0.86
Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol (2013) 0.85
Chemical labels metabolically installed into the glycoconjugates of the target cell surface can be used to track lymphocyte/target cell interplay via trogocytosis: comparisons with lipophilic dyes and biotin. Immunol Invest (2007) 0.84
Moderate strength (0.23-0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells. BMC Genomics (2009) 0.83
Extracellular and intracellular esterase processing of SCFA-hexosamine analogs: implications for metabolic glycoengineering and drug delivery. Bioorg Med Chem Lett (2012) 0.82
Targeting cancer cells with dendrimers. Chem Biol (2005) 0.81
Development of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogs. Glycoconj J (2010) 0.79
Sialic acid and the central nervous system: perspectives on biological functions, detection, imaging methods and manipulation. CNS Neurol Disord Drug Targets (2006) 0.78
Differential response of chondrocytes and chondrogenic-induced mesenchymal stem cells to C1-OH tributanoylated N-acetylhexosamines. PLoS One (2013) 0.78
Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. Appl Immunohistochem Mol Morphol (2016) 0.77
Short-chain fatty acid-modified hexosamine for tissue-engineering osteoarthritic cartilage. Tissue Eng Part A (2013) 0.77
DmSAS is required for sialic acid biosynthesis in cultured Drosophila third instar larvae CNS neurons. ACS Chem Biol (2011) 0.77
A photochemical snapshot of CD22 binding. Nat Chem Biol (2005) 0.76
Experimental Design Considerations for In Vitro Non-Natural Glycan Display via Metabolic Oligosaccharide Engineering. Curr Protoc Chem Biol (2010) 0.76
Deciphering glycan linkages involved in Jurkat cell interactions with gold-coated nanofibers via sugar-displayed thiols. Bioorg Med Chem Lett (2011) 0.75
Comparative evaluation of chitosan, cellulose acetate, and polyethersulfone nanofiber scaffolds for neural differentiation. Carbohydr Polym (2013) 0.75
Electrochemically active, anti-biofouling polymer adlayers on indium-tin-oxide electrodes. Chem Commun (Camb) (2008) 0.75
Activity of human P450 2D6 in biphasic solvent systems. Biotechnol Bioeng (2007) 0.75
Another incentive to lose weight. Aust Fam Physician (2006) 0.75
Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogs used in Metabolic Glycoengineering. Mol Pharm (2017) 0.75